[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Temkin SM, Yamada SD, Fleming GF: A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol; 2010 Jun;117(3):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient characteristics included ovarian cancer (n=7), endometrial cancer (n=3), uterine carcinosarcoma (n=3), and cervical cancer (n=2); performance status 0 (n=10) and 1 (n=5); prior chemotherapy regimens one (n=8), two (n=4), and three (n=3).
  • The regimen may be safe in women who have not previously received radiation, but full doses of each agent could not be administered in combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Genital Neoplasms, Female / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Sirolimus / administration & dosage. Sirolimus / adverse effects. Sirolimus / analogs & derivatives. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20347480.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 624KN6GM2T / temsirolimus; 7M7YKX2N15 / Topotecan; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


2. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC: Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res; 2007 Apr 01;13(7):2128-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A fully human monoclonal antibody to anti-alpha(v) integrins (CNTO 95) has been shown to inhibit angiogenesis and tumor growth in preclinical studies.
  • Pre- and post-treatment lesion biopsies confirmed tumor cell alpha(v) integrin expression, as well as CNTO 95 penetration of the tumor and localization to tumor cells in association with reduced bcl-2 expression.
  • A lesion in one patient (10.0 mg/kg) with stable ovarian carcinosarcoma was no longer detectable by FDG-PET by day 49.
  • Biopsy data confirmed tumor localization and pharmacodynamic activity.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacokinetics. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Integrin alphaV / metabolism. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Positron-Emission Tomography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404096.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601746
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Integrin alphaV
  •  go-up   go-down


3. Ide Y, Nakahara T, Nasu M, Tominaga N, Ohyama A, Tachibana T, Yasuda M: Establishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs. Hum Cell; 2009 Aug;22(3):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs.
  • A cell line designated as NEYS was established from ovarian carcinosarcoma (stage IIIc) of a 56-year-old Japanese woman.
  • The extirpated original tumor was carried in growth medium at 0 degrees C to the culture room.
  • This cell line is useful for studies on the histogenesis of carcinosarcoma and susceptibility of cancer drugs in human ovarian carcinosarcoma.
  • The immunohistochemical and ultrastructual analysis demonstrated that NEYS cells showed epithelial and mesenchymal differentiation, and supported the metaplasis theory as the cause of carcinosarcoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, Neoplasm. Cell Culture Techniques. Cell Line, Tumor. Chromosomes. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1993 Feb;24(2):132-42 [7679366.001]
  • [Cites] Am J Obstet Gynecol. 1954 Aug;68(2):652-8 [13180575.001]
  • [Cites] Ann Oncol. 1995 Oct;6(8):755-8 [8589011.001]
  • [Cites] Arch Pathol Lab Med. 1991 Jun;115(6):583-90 [1710102.001]
  • [Cites] Hum Cell. 1999 Mar;12(1):3-10 [10457900.001]
  • [Cites] Obstet Gynecol. 1988 Sep;72(3 Pt 1):409-12 [2841630.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):103-12 [6317155.001]
  • [Cites] Hum Cell. 2004 Sep;17(3):131-7 [15859158.001]
  • [Cites] Gynecol Oncol. 1987 Jun;27(2):189-96 [3570057.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):278-92 [6086467.001]
  • [Cites] Am J Surg Pathol. 1980 Feb;4(1):37-42 [6244746.001]
  • [Cites] Obstet Gynecol. 1985 May;65(5):720-4 [2984621.001]
  • [Cites] Exp Pathol. 1986;30(1):21-32 [3019754.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jan;13(1):22-8 [8112953.001]
  • [Cites] Cancer. 1971 Jan;27(1):207-16 [4321899.001]
  • [Cites] Pathol Int. 2001 May;51(5):380-4 [11422797.001]
  • [Cites] Obstet Gynecol. 1977 Jan;49(1 suppl):59-63 [831181.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1241-52 [6328089.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):523-32 [11733966.001]
  • [Cites] Cancer Res. 1981 May;41(5):1978-83 [7194144.001]
  • [Cites] Hum Cell. 2004 Sep;17(3):139-44 [15859159.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1209-13 [8630899.001]
  • (PMID = 19624308.001).
  • [ISSN] 1749-0774
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Pearl ML, Inagami M, McCauley DL, Valea FA, Chalas E, Fischer M: Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):745-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the records of all patients who had received the MAID regimen for a gynecological sarcoma between 1993 and 2000.
  • We did not observe any responses among the patients with carcinosarcomas of either ovarian or uterine origin.
  • It remains to be established if any combination chemotherapy regimen is better than single agent treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / pathology. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Medical Records. Mesna / administration & dosage. Middle Aged. Neoplasm Staging. New York. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Retrospective Studies. Survival Analysis. Treatment Outcome. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / mortality. Vulvar Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445253.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


5. Lavie O, Longacre T, Segev Y, Husain A: Ovarian carcinosarcomas associated with prolonged use of tamoxifen: case reports. Int J Gynecol Cancer; 2009 Dec;19(9):1521-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinosarcomas associated with prolonged use of tamoxifen: case reports.
  • BACKGROUND: Recent studies have indicated that the risk associated with tamoxifen may be substantially higher for uterine malignant mixed müllerian tumors and uterine sarcomas.
  • CASE: We present 2 cases of ovarian carcinosarcomas in patients with a personal history of breast carcinoma who were treated for a prolonged period with tamoxifen.
  • CONCLUSIONS: To our knowledge, these 2 cases are the first to describe the possible association between ovarian carcinosarcomas and previous personal and familial history of breast carcinoma andor prolonged use of tamoxifen.
  • [MeSH-major] Carcinosarcoma / chemically induced. Ovarian Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Female. Humans. Middle Aged. Neoplasms, Second Primary / chemically induced. Time Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955929.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


6. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer; 2004 May 15;100(10):2148-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the ovary: 19 years of prospective data from a single center.
  • BACKGROUND: A review of clinicopathologic features and outcome in women with carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of the ovary was conducted.
  • METHODS: Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma and 70 patients with ovarian carcinosarcoma underwent treatment at the Edinburgh Cancer Centre.
  • Analysis was performed on 65 patients with MMMT, and 746 patients with SAC were selected as a group for comparison.
  • RESULTS: Patients with carcinosarcoma had a mean age of 66.6 years, which is significantly older than those with SAC (62.0 years) (P < 0.001).
  • The objective response rate to platinum-based chemotherapy was found to be significantly lower in patients with carcinosarcoma (25% vs. 60%; P = 0.02).
  • Cause-specific survival in the carcinosarcoma group was poor and significantly shorter than that observed in the SAC group (median survival of 8.2 months vs. 20.7 months; P < 0.0001).
  • Progression-free survival in patients with carcinosarcoma also was found to be significantly shorter compared with patients with SAC (median progression-free survival of 6.4 months vs. 12.1 months; P < 0.001).
  • Achieving optimal debulking at the time of initial surgery was found to be a highly significant factor in patients with carcinosarcoma with regard to determining outcome (median survival of 14.8 months for patients with optimally debulked International Federation of Gynecology and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/nondebulked Stage III disease; P < 0.001).
  • CONCLUSIONS: Ovarian carcinosarcoma is a distinct entity with a poor prognosis.
  • Patients with carcinosarcoma differ from those with SAC with regard to having an older mean age of onset, an inferior response to platinum-based chemotherapy, and worse progression-free and cause-specific survival.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / mortality. Cystadenoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Matsuo K, Bond VK, Im DD, Rosenshein NB: Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay. Am J Clin Oncol; 2010 Aug;33(4):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
  • OBJECTIVES: To evaluate the role of an in vitro drug resistance assay to predict the response to platinum and taxane combination chemotherapy in advanced ovarian and uterine carcinosarcoma.
  • METHODS: We evaluated all patients with FIGO stage II-IV ovarian and FIGO stage III-IV uterine carcinosarcoma, who received platinum and taxane chemotherapy after initial cytoreductive surgery between January 1, 1995 and March 31, 2008.
  • In vitro drug resistance assay results (Extreme Drug Resistance [EDR] Assay, Oncotech Inc, Tustin, CA) were evaluated.
  • RESULTS: There were 51 cases in which in vitro drug resistance assay results were available, of which 17 (33.3%) received combination chemotherapy with platinum and taxane.
  • For these 17 cases, the primary site of disease was ovary in 12 cases and uterus in the other 5 cases.
  • Chemotherapy response in the presence of EDR to at least 1 of the 2 drugs (EDR-PT) was significantly lower than non-EDR-PT (37.5% vs. 100%, P = 0.009).
  • CONCLUSIONS: Use of an in vitro drug resistance assay was a feasible test to predict the chemotherapy response and survival outcome in advanced ovarian and uterine carcinosarcoma.
  • [MeSH-major] Carcinosarcoma / drug therapy. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Taxoids / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / therapeutic use. Predictive Value of Tests. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875949.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS: Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol; 2003 Apr;89(1):60-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression.
  • OBJECTIVE: Primary peritoneal carcinosarcomas are similar to ovarian carcinomas in that they can metastasize by intraperitoneal dissemination; therefore, invasion of the submesothelial interstitial (stromal) matrix is an integral part of the pathology.
  • Our objective was to study cell-matrix interactions that may influence invasive behavior of a novel, primary peritoneal carcinosarcoma cell line (PC880), and to assess how these cell-matrix interactions are different from frequently studied cultured ovarian carcinoma cells NIH:OVCAR-3, SKOV-3, and ES-2.
  • METHODS: The PC880 cell line was established from ascites fluid of a patient diagnosed with primary peritoneal carcinosarcoma.
  • Invasion assays were done using a three-dimensional type I collagen gel.
  • The cells also adhered to type I collagen and invaded a three-dimensional type I collagen matrix.
  • The ES-2 cells also adhered to type I collagen, and invaded the three-dimensional type I collagen matrix; however, inhibitors such as heparin, chondroitin sulfate, function-blocking antibody to alpha2 integrin, E-64, and AEBSF were less effective in moderating the invasiveness.
  • The NIH:OVCAR-3 and SK-OV-3 cells were previously found to adhere to type I collagen, but these cells did not invade the three-dimensional type I collagen matrix.
  • In a monolayer culture PC880 and ES-2 cells had significantly higher motility than NIH:OVCAR-3 and SK-OV-3 cells.
  • CONCLUSIONS: PC880 is the first cell line established from primary peritoneal carcinosarcoma, and the cytoskeletal composition indicated that these cells represent the sarcomatous elements of the tumor.
  • PC880 cells, similar to ES-2 cells, adhered to type I collagen, and invaded a three-dimensional collagen matrix.
  • The invasion of the interstitial matrix by both the peritoneal carcinosarcoma and the ovarian carcinoma cell line was mediated by cell surface proteoglycans, alpha2 integrin, and proteases.
  • The invasive cell behavior of PC880 and ES-2 cells correlated with a high degree of motility, and with the lack of expression of the cell-cell adhesion molecule E-cadherin.
  • [MeSH-major] Cadherins / physiology. Carcinosarcoma / pathology. Cell Adhesion Molecules / physiology. Endopeptidases / physiology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Tumor Cells, Cultured / pathology
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Movement / physiology. Chondroitin / pharmacology. Collagen Type I / metabolism. Extracellular Matrix / metabolism. Female. Fibronectins / metabolism. Heparin / pharmacology. Humans. Integrin alpha2 / biosynthesis. Integrin alpha2 / physiology. Laminin / metabolism. Middle Aged. Neoplasm Invasiveness. Protease Inhibitors / pharmacology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Rats. Vitronectin / metabolism


9. Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC: The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol; 2009 Dec;115(3):377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
  • OBJECTIVES: To evaluate the response rate and toxicity of a regimen comprised of monthly carboplatin and weekly paclitaxel for recurrent ovarian cancer.
  • METHODS: We performed a retrospective chart review of patients with recurrent ovarian cancer treated between 2001 and 2006 at a single institution with carboplatin AUC 5 (day 1), and paclitaxel 80 mg/m(2) (days 1, 8, 15) of a 28-day cycle.
  • Stage ranged from stages IC to IV.
  • Histologic subtypes included papillary serous (17), carcinosarcoma (1), and clear cell (2).
  • CONCLUSIONS: A monthly carboplatin and weekly paclitaxel regimen is highly active for women with recurrent platinum-sensitive and platinum-resistant epithelial ovarian cancer.
  • This pilot series demonstrates the potential for this regimen as treatment of choice among doublet first salvage regimens for patients with recurrent epithelial ovarian cancer, thus warranting multi-institutional study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19800107.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Näyhä V, Stenbäck F: Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. APMIS; 2008 Feb;116(2):107-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas.
  • Carcinosarcomas of the female genital tract are a heterogeneous group of aggressive malignant neoplasms characterized by poor prognosis that contain elements expressing both carcinomatous and sarcomatous characteristics.
  • In areas around tumor islets expressing predominantly epithelial carcinomatous characteristics, microvessel density was increased three-fold compared with the islets themselves.
  • Vessels were arranged in a garland-type pattern, or in bursts, and they exhibited directional angiogenesis.
  • Clinical indicators of poor survival were high tumor stage (p=0.002) and age above 65 (p=0.0769).
  • Tumor tissue area above the median exhibiting VEGF expression was also a sign of poor survival (p=0.0267), as was an area of positive staining for VEGFR-3 exceeding the median (p=0.00487).
  • In this study, active angiogenesis (increased number of vessels, variable in shape and exhibiting decreased antibody staining intensity) was a distinct feature of carcinosarcomas, its extent and distribution depending upon neoplasm morphology.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Carcinosarcoma / blood supply. Neovascularization, Pathologic / metabolism. Ovarian Neoplasms / blood supply. Uterine Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321361.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / F8 protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9001-27-8 / Factor VIII; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


11. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD, Gynecologic Oncology Group: Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol; 2004 May;93(2):336-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study.
  • OBJECTIVES: Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions.
  • This report presents data on cisplatin, the first of the agents to be studied in this disease.
  • METHODS: One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m(2)) every 3 weeks until disease progression or unacceptable toxicity.
  • CONCLUSIONS: These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinosarcoma / drug therapy. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099942.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 12477; United States / NCI NIH HHS / CA / CA 12482; United States / NCI NIH HHS / CA / CA 12484; United States / NCI NIH HHS / CA / CA 12485; United States / NCI NIH HHS / CA / CA 12534; United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 15975; United States / NCI NIH HHS / CA / CA 15977; United States / NCI NIH HHS / CA / CA 16386; United States / NCI NIH HHS / CA / CA 16938; United States / NCI NIH HHS / CA / CA 19502; United States / NCI NIH HHS / CA / CA 21720; United States / NCI NIH HHS / CA / CA 21946; United States / NCI NIH HHS / CA / CA 23073; United States / NCI NIH HHS / CA / CA 23088; United States / NCI NIH HHS / CA / CA 23501; United States / NCI NIH HHS / CA / CA 23765; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 28160; United States / NCI NIH HHS / CA / CA 34477; United States / NCI NIH HHS / CA / CA 35640; United States / NCI NIH HHS / CA / CA 37234; United States / NCI NIH HHS / CA / CA 37569; United States / NCI NIH HHS / CA / CA 40296; United States / NCI NIH HHS / CA / CA13633; United States / NCI NIH HHS / CA / CA37535
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Takami M, Idei T, Nakayama Y, Ohta H, Fukai H, Matsumoto H, Togo Y, Sakamoto H, Yamamoto T, Satoh K: [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan To Kagaku Ryoho; 2002 Feb;29(2):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
  • Carcinosarcoma of the ovary is a very rare and highly malignant neoplasm that accounts for less than 1% of ovarian neoplasms.
  • We report the case of a 60-year-old woman who had Stage IV advanced heterogeneous ovarian carcinosarcoma with lung and liver metastases.
  • Tumor markers of CA125 and LDH decreased remarkably to the normal level after 3 and 4 courses of chemotherapy, respectively.
  • After 7 courses of chemotherapy, the ovarian tumor was obviously reduced, and the lung and liver metastases had disappeared.
  • The current case suggests that combination CPT-11 and CDDP is effective against advanced ovarian carcinosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterotomy. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P, Caspani G, Battistello M, Colombo N: Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int J Gynecol Cancer; 2009 Aug;19(6):1142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
  • BACKGROUND: Ovarian carcinosarcoma (OCS) is a rare malignancy associated with a poor prognosis.
  • Platinum, anthracyclines, and alkylating agents are the most effective antiblastic drugs for treatment of gynecologic epithelial and stromal tumors.
  • The aim of this study was to determine response rate and overall survival (OS) of patients with OCS who were treated with a combination of these 3 drugs.
  • RESULTS: Four women had OCS stage I; 7, stage II; 23, stage III; and 7, stage IV.
  • Heterologous, homologous, and mixed stromal components were described in 17, 14, and 10 patients, respectively.
  • Overall progression-free survival was 11.8 months (range, 0.9-96 months) and 13.8 and 10.1 months in stage I-II and III-IV, respectively (P = 0.13).
  • Median OS was 20 months (range, 1-123 months), not reached in stage I-II, and 19.7 months in stage III-IV (P = 0.07).
  • No significant difference between homologous and heterologous sarcomatous components was observed (P = 0.95), whereas no significant trend of improved OS was noticed for stage IIIC-IV with optimal debulking surgery (n = 9), compared with suboptimal cytoreduction (n = 19; 32.6 vs 14.5 months, P = 0.14).
  • CONCLUSION: The combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity.
  • Optimal cytoreduction may improve survival, but new anticancer drugs or more effective regimens are awaited.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy. Platinum Compounds / administration & dosage

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820383.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents, Alkylating; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Comander AH, Cannistra SA: A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):51-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.
  • To determine the tolerability of oral maintenance topotecan when administered to patients with advanced ovarian, fallopian tube, and primary peritoneal serous cancers who have achieved a complete clinical response after first-line platinum-based therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Fallopian Tube Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Carcinosarcoma / drug therapy. Feasibility Studies. Female. Humans. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506844.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


15. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E: Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol; 2008 Jan;108(1):136-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
  • OBJECTIVE: To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas.
  • CONCLUSIONS: Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas.
  • Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas.
  • We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936342.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Turbiner J, Moreno-Bueno G, Dahiya S, Sánchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J: Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol; 2008 Aug;21(8):925-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A control group included 15 patients with endometrial carcinoma and associated ovarian hyperthecosis and one patient with endometrial carcinoma and adult granulosa cell tumor of the ovary, chosen because both conditions are associated with increased production of estrogen and increased risk of endometrial carcinoma development.
  • There were 16 endometrioid endometrial carcinomas, one mixed carcinoma and one clear cell carcinoma among patients in the tamoxifen group.
  • All patients with ovarian hyperthecosis and adult granulosa cell tumor had endometrioid endometrial carcinoma.
  • In the random control group, there were 26 endometrioid endometrial carcinomas and one carcinosarcoma.
  • Immunohistochemical and mutational analysis for beta-catenin showed abnormalities in 4/11 (36%) and 3/10 (30%) informative cases in the tamoxifen group; 7/16 (44%) and 4/15 (27%) informative cases, respectively in the ovarian hyperthecosis group and 1/27 random control cases (4%) (P<0.05).
  • In conclusion, there was a direct relationship between tamoxifen exposure and overexpression of beta-catenin oncoprotein, which is known to play a major role in the pathogenesis of estrogen-driven, type I endometrial adenocarcinoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / pathology. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / chemically induced. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Microsatellite Instability. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins p21(ras) / genetics. Proto-Oncogene Proteins p21(ras) / metabolism. Survival Rate. beta Catenin / genetics. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500270.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / beta Catenin; 094ZI81Y45 / Tamoxifen; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


17. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M, Awada A: Current management of ovarian carcinosarcoma. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):316-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of ovarian carcinosarcoma.
  • Ovarian carcinosarcomas (OCS), also known as malignant mixed müllerian tumors, are uncommon malignancies that carry a poor prognosis.
  • The presentation of OCS is usually indistinguishable from that of epithelial ovarian cancer.
  • However, poor performance status at presentation is also a common problem, so that many patients may be unsuitable for combination chemotherapy but may still benefit from single-agent platinum or ifosfamide or, occasionally, from nonplatinum schedules such as ifosfamide plus paclitaxel.
  • [MeSH-major] Carcinosarcoma / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Humans. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362309.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 87
  •  go-up   go-down


18. Wei F, Jiang Z, Yan C: Analysis of 20 mature ovarian cystic teratoma cases in postmenopausal women. Chin Med J (Engl); 2001 Feb;114(2):137-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 20 mature ovarian cystic teratoma cases in postmenopausal women.
  • OBJECTIVE: To study the incidence of malignant change, diagnosis and management of mature cystic teratomas in postmenopausal women.
  • RESULTS: The number of postmenopausal patients with mature cystic teratoma (20) accounted for 7.6% of the total number of patients with benign ovarian teratomas (263).
  • There were 3 cases of malignant change, which were squamous carcinoma, carcinosarcoma, and digestive gland epithelial carcinoma.
  • The incidence of malignant change was 15%.
  • CONCLUSION: In postmenopausal women, mature ovarian cystic teratoma should be treated as lowly malignant and should be paid much attention.
  • [MeSH-major] Ovarian Neoplasms / pathology. Postmenopause. Teratoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy. Female. Humans. Hysterectomy. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780192.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement